 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...93949596979899100101102103...235236» |
- | Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche
Enrollment open: A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) (clinicaltrials.gov) - May 5, 2022
P2, N=30, Recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting
- | New trial, Surgery: Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer (clinicaltrials.gov) - May 5, 2022
P=N/A, N=89, Recruiting, Sponsor: Cho Ray Hospital
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: SINAI: Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - May 5, 2022
P2, N=60, Not yet recruiting, Sponsor: National Taiwan University Hospital
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Here is my take: if high risks of systemic relapse (T4, N2 etc), I start with chemo- FOLFIRINOX in fit patients (PRODIGE 23). Pls note OPRA had only 11% T4 pts in CRT-->CNCT arm and data on N1 vs. N2 not provided, 5% pts had high-grade histology. I worry about distant relapses. (Twitter) - May 4, 2022
- | New P2 trial, Metastases: Redefining FOLFIORINOX in Older Pancreatic Cancer Patients (clinicaltrials.gov) - May 4, 2022
P2, N=37, Not yet recruiting, Sponsor: Fox Chase Cancer Center
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Targeted Therapy for Colorectal Cancer. (Pubmed Central) - May 4, 2022
Patients with mCRC with KRAS/NRAS/BRAF wild-type left-sided tumors may benefit from epidermal growth factor receptor (EGFR) inhibition with either cetuximab or panitumumab, in conjunction with chemotherapy...The vascular endothelial growth factor (VEGF) inhibitor bevacizumab can serve as an alternative to EGFR inhibitors in right-sided tumors or second-line therapy...Triple combination therapy with cetuximab, the BRAF inhibitor encorafenib, and the MEK kinase inhibitor binimetinib has extended overall survival by about 3 months compared with chemotherapy alone...The KEYNOTE-177 trial demonstrated that therapy with single-agent pembrolizumab improved progression-free survival by 8 months compared with FOLFOX or FOLFIRI and with or without EGFR inhibition. At this time, targeted therapy should only be used in patients with unresectable metastatic disease.
- | Avastin (bevacizumab) / Roche
Retrospective data, Journal: FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. (Pubmed Central) - May 4, 2022
P3
At this time, targeted therapy should only be used in patients with unresectable metastatic disease. Upfront FOLFOXIRI/bev shows a favourable efficacy/safety balance in EO-mCRC.
- | Avastin (bevacizumab) / Roche
Journal: Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. (Pubmed Central) - May 4, 2022
P3
Upfront FOLFOXIRI/bev shows a favourable efficacy/safety balance in EO-mCRC. Mebendazole may represent an attractive candidate for drug repositioning against mCRC secondary to its safety and efficacy in enhancing tumor response to chemotherapy.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
P3 data, Journal, Mismatch repair, Microsatellite instability: Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. (Pubmed Central) - May 4, 2022
P3
In this updated analysis, although pembrolizumab continued to show durable antitumour activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups. These findings support pembrolizumab as an efficacious first-line therapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: I would give FOLFOX. Although limited experience but I have given FLOT to 4 patients so far and none them tolerated it. (Twitter) - May 3, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
not much role for post op XRT following ARTIST1,2 CRITICS trial following D2 surgery , can make a case for either FOLFOX or FLOT (Twitter) - May 3, 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Observational data, Review, Journal: Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer. (Pubmed Central) - May 3, 2022
In BEACON CRC, overall survival (OS) was significantly longer for patients receiving encorafenib plus cetuximab ± binimetinib when compared with irinotecan/FOLFIRI plus cetuximab as second- and third-line therapy...Patients with BRAF-mutant mCRC have worse outcomes with conventional therapy vs patients with BRAF wild-type tumours. BRAF inhibitors in conjunction with anti-EGFR therapy improves outcomes for patients with BRAF-mutant mCRC vs conventional therapy or a BRAF inhibitor alone.
- || Avastin (bevacizumab) / Roche
Clinical data, Journal: Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only. (Pubmed Central) - May 3, 2022
No significant differences regarding PFS and OS (both P > 0.05) between the three groups of patients with mCRC were observed. Our study revealed that in patients with PC-only mCRC treatment of first-line bevacizumab and FOLFIRI through irinotecan dose escalation according to UGT1A1 polymorphism could confer such patients with comparable outcomes to that of patients with LiM-only and LuM-only mCRC.
- | Hetronifly (serplulimab) / Fosun Pharma, pimurutamab (HLX07) / Fosun Pharma
Trial initiation date, Monotherapy: Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC (clinicaltrials.gov) - May 3, 2022
P2, N=50, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
Our study revealed that in patients with PC-only mCRC treatment of first-line bevacizumab and FOLFIRI through irinotecan dose escalation according to UGT1A1 polymorphism could confer such patients with comparable outcomes to that of patients with LiM-only and LuM-only mCRC. Initiation date: Apr 2022 --> Jul 2022
- | New P2 trial: Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer (clinicaltrials.gov) - May 2, 2022
P2, N=38, Not yet recruiting, Sponsor: Rutgers, The State University of New Jersey
- | Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Enrollment change, Trial termination: Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma (clinicaltrials.gov) - May 2, 2022
P2, N=31, Terminated, Sponsor: University of California, San Diego
Initiation date: Apr 2022 --> Jul 2022 N=100 --> 31 | Active, not recruiting --> Terminated; Original investigator for the trial has left
- | Jakafi (ruxolitinib) / Incyte
Trial termination: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2022
P2, N=11, Terminated, Sponsor: M.D. Anderson Cancer Center
N=100 --> 31 | Active, not recruiting --> Terminated; Original investigator for the trial has left Completed --> Terminated; Study was closed early due to low accrual and lack of response.
- | epacadostat (INCB024360) / Incyte
Trial completion date, Trial primary completion date: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - May 2, 2022
P1, N=39, Recruiting, Sponsor: Washington University School of Medicine
Completed --> Terminated; Study was closed early due to low accrual and lack of response. Trial completion date: Nov 2024 --> Jun 2027 | Trial primary completion date: Jul 2024 --> Dec 2026
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
ABCSG P02: A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer (Gallery A) - May 1, 2022 - Abstract #OeGHOAHOP2022OeGHO_AHOP_332;
Trial completion date: Nov 2024 --> Jun 2027 | Trial primary completion date: Jul 2024 --> Dec 2026 Hypothesis: Superiority of neoadjuvant chemotherapy followed by neoadjuvant radiochemotherapy compared to neoadjuvant chemotherapy alone in terms of R0 resectability Study population: patients with locally advanced, primarily inoperable pancreatic cancer Introductory: expected by the end of Q1 2023.
- dronabinol oral / Generic mfg.
AGMT_DISCOVER: Multicenter-randomized, double-blind- placebo-controlled, phase-III-clinical-trial to investigate efficacy + safety of Dronabinol in the Improvement of ChemOthErapy-induced and tumor-Related-symptoms in patients with locally- advanced or metastatic pancreatic-cancer during first-line-chemotherapy (Gallery A) - May 1, 2022 - Abstract #OeGHOAHOP2022OeGHO_AHOP_317;
Population: Adult patients (≥ 18 years) with diagnosis of locally advanced or metastatic pancreatic cancer, assigned to first-line chemotherapy with FOLFIRINOX or gemcitabine + Abraxane®. Primary endpoint: The primary endpoint variable is the standardized area under the curve of the EORTC QLQ-C30 symptom summary score over the on-treatment period (scores at visits 1–9).
- | Journal: Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. (Pubmed Central) - Apr 30, 2022
In this review, we study two decades of efforts to improve upon the gemcitabine backbone - 67 phase II and III trials enrolling 16,446 patients - that culminated in the approvals of gemcitabine/nab-paclitaxel (Gem/NabP) and FOLFIRINOX...Hence, we conclude this review by summarizing the data that ultimately demonstrate a small but significant survival benefit of second-line therapy with Gem/NabP or FOLFIRINOX. Collectively, these studies describe the long journey, the steady effort, and the myriad lessons to be learned from 20 years of PDAC trials to inform strategies for success in clinical trials moving forward.
- | Journal, HEOR: Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans. (Pubmed Central) - Apr 30, 2022
Gem/NabP appeared noninferior to FOLFIRINOX for survival outcomes for advanced pancreatic adenocarcinoma based on national VA data. Biomarker-based growth equations may be useful for monitoring treatment response and predicting prognosis for pancreatic cancer.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal: Treatment sequencing of metastatic colorectal cancer based on primary tumor location. (Pubmed Central) - Apr 30, 2022
Patients whose primary tumor originates from the left side of the colon and whose tumor's genome encodes wild-type RAS and BRAF should be offered cetuximab or panitumumab in the first-line treatment of metastatic disease or in subsequent lines...Specifically, an aggressive initial approach with FOLFOXIRI plus bevacizumab is a treatment option in right-sided tumors under investigation. This report reviews the available data for the treatment of metastatic colorectal cancer according to the location of the primary tumor and proposes the optimal treatment sequencing strategy incorporating the site of origin of the tumor and molecular information into the decision-making process.
- | Journal: Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer. (Pubmed Central) - Apr 30, 2022
The CDM directly (intratumoral) injected into pancreatic cancers in orthotopic models through an invasive approach significantly delayed the tumor progression by combinational photo-chemotherapy with less toxic side effects. This study offers a promising and alternative approach for safe and more effective pancreatic cancer treatment via prodrug nanoparticles that combine photodynamic therapy and chemotherapy.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. (Pubmed Central) - Apr 29, 2022
This study offers a promising and alternative approach for safe and more effective pancreatic cancer treatment via prodrug nanoparticles that combine photodynamic therapy and chemotherapy. We failed to increase from 50 to 70% the R0/R1 liver-resection rate with the use of 3-CTx combined with bevacizumab or cetuximab by RAS status in CRC patients with initially unresectable liver metastases.
- | leucovorin calcium / Generic mfg.
Journal: The interactions of folate with the enzyme furin: a computational study. (Pubmed Central) - Apr 29, 2022
While the folic acid molecule tended to be positioned slightly towards the Glu271, Tyr313, Ala532, Gln488, and Asp530 amino acids of furin at short and long ranges, the folinic acid molecule interacted with Glu271, Ser311, Arg490, Gln488, and Lys499 amino acids. Consequently, binding free energy calculations illustrated that folic acid (-27.90 kcal mol) has better binding in comparison with folinic acid (-12.84 kcal mol).
- | Cyramza (ramucirumab) / Eli Lilly
Trial completion date, Combination therapy: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) - Apr 29, 2022
P2/3, N=180, Active, not recruiting, Sponsor: Institut f
Consequently, binding free energy calculations illustrated that folic acid (-27.90 kcal mol) has better binding in comparison with folinic acid (-12.84 kcal mol). Trial completion date: Mar 2022 --> Jun 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2022
P2, N=196, Recruiting, Sponsor: Institut f
Trial completion date: Mar 2022 --> Jun 2022 Trial primary completion date: Mar 2022 --> Sep 2022
- ||||| Vyloy (zolbetuximab-clzb) / Astellas
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Spotlight: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov) - Apr 29, 2022
P3, N=566, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial primary completion date: Mar 2022 --> Sep 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: May 2022 --> Aug 2022
- | Avastin (bevacizumab) / Roche
New P2 trial, Surgery: Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases (clinicaltrials.gov) - Apr 28, 2022
P2, N=168, Not yet recruiting, Sponsor: Sun Yat-sen University
- | New P2 trial: Re-Play: Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin (clinicaltrials.gov) - Apr 28, 2022
P2, N=25, Recruiting, Sponsor: Instituto do Cancer do Estado de S
- | leucovorin calcium / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant (clinicaltrials.gov) - Apr 28, 2022
P2, N=46, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: May 2022 --> Aug 2022 Trial primary completion date: Dec 2021 --> Dec 2022
- || Nypta (tideglusib) / ASD Therap
Retrospective data, Review, Journal: Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. (Pubmed Central) - Apr 28, 2022
Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: A Case of Advanced Gastric Cancer Successfully Treated with FOLFOX (Pubmed Central) - Apr 28, 2022
Partial response was maintained until the onset of oxaliplatin drug allergy in the 10th course. FOLFOX is a promising option for patients with difficulties in oral intake.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection (Pubmed Central) - Apr 28, 2022
The long-term survival has been continued for 7 years and 7 months after first operation. It was considered that laparoscopic surgery for peritoneal recurrence in colorectal cancer is contributed to one of the surgical procedures in selected patients.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Retrospective data, Journal: 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice. (Pubmed Central) - Apr 28, 2022
Two patients with controlled disease had homologous recombination deficiency (HRD)-associated gene mutations in cancer panel testing. The FOLFOX regimen benefit for UR-PC patients treated with GnP and 5-FU/LV plus nal-IRI may be limited to patients with HRD-associated gene mutations.
- || Aphexda (motixafortide) / BioLineRx, Ayrmid
Trial completion date, Trial primary completion date, Metastases: COMBAT: Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Apr 28, 2022
P2a, N=80, Active, not recruiting, Sponsor: BioLineRx, Ltd.
The FOLFOX regimen benefit for UR-PC patients treated with GnP and 5-FU/LV plus nal-IRI may be limited to patients with HRD-associated gene mutations. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes – An Observational Study () - Apr 28, 2022 - Abstract #ESA2022ESA_53;
Multivariate analysis showed that FOLFIRINOX, PCI, retroperitoneal lymph node metastases, and pathological response as independent survival predictors. Further studies are needed to determine the best neoadjuvant chemotherapy strategy and to confirm our findings in larger multicentric studies.
- Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
Real-world (RW) treatment patterns and clinical outcomes for chemotherapy-based regimens in first line (1L) MSI-H/dMMR metastatic colorectal cancer (mCRC). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6145;
This data further supports the rationale for biomarker testing and personalized treatment of 1L CRC. Patient characteristics and clinical outcomes are summarized in the table.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., lenvatinib / Generic mfg.
Lenvatinib combined with hepatic arterial infusion of modified FOLFOX regime as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6086;
Lenvatinib combined with FOLFOX-HAIC was well tolerated and had shown promising ORR, PFS rates in patients with intermediate-stage HCC beyond up-to-seven criteria. A prospective large-scale trial is needed to justify these results.
- Pathologic and clinical outcomes after neoadjuvant modified FOLFIRINOX and gemcitabine and NAB-paclitaxel for pancreatic cancer. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6082;
Differences in survival outcomes between the two NAC regimens were not significantly different, and outcomes were comparable to those reported in the phase II SWOG S1505 trial. Large prospective trials comparing these two regimens in terms of efficacy and toxicity will be required to better answer these questions.
- Tomudex (raltitrexed) / Pfizer, AstraZeneca
Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil in intermediate and advanced hepatocellular carcinoma: A retrospective study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6078;
HAIC with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) was most commonly used in China. The efficacy and safety of HAIC with raltitrexed plus oxaliplatin was comparable to HAIC with oxaliplatin plus fluorouracil in intermediate and advanced HCC.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Survival outcomes amongst patients with new onset diabetes preceding the diagnosis of pancreatic adenocarcinoma: Multicenter retrospective study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6058;
Pts with NOD preceding PDAC were shown to have worse survival outcomes in the resected cohort. Larger studies need to be conducted in this context as this could have significant implications for PDAC screening and treatment.
- albumin-bound paclitaxel / Generic mfg.
Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer and borderline pancreatic inoperable cancers. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6056;
P1
Neoadjuvant FOLFIRINOX or GnP followed by SBRT in patients with LAPC is feasible and shows antitumor activity. There were no safety concerns or treatment delays with incorporation of SBRT.
- adagrasib (MRTX849) / Mirati, IMM-1-104 / Immuneering, Lumakras (sotorasib) / Amgen
Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus sotorasib or adagrasib in KRAS mutant pancreatic tumors. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6049;
The Phase 2 KRYSTAL-1 and Phase 1/2 CodeBreaK 100 studies recently reported promising activity in KRAS-G12C PDAC, suggesting an opportunity for disruption of KRAS addiction. IMM-1-104 and sotorasib previously demonstrated comparable tumor regressions in vivo in a KRAS G12C mutant model, MIA PaCa-2 (2021 EORTC).
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6048;
Of the 18 patients enrolled, 10 received Gemcitabine/Cisplatin, while 8 patients received either Gemcitabine monotherapy or Capecitabine or FOLFIRI alone or with Cetuximab... To our knowledge, this is the first report to show improved overall survival outcomes with Gemcitabine plus Cisplatin as neo-adjuvant treatment with no concomitant radiation compared to non-Gemcitabine/ Cisplatin regimens in patients with CCA prior to liver transplantation.
- vactosertib (TEW-7197) / National OncoVenture, Medpacto
Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/nab-paclitaxel. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6032;
P1b
In this phase Ib study, we demonstrated the feasibility and safety of adding vactosertib to FOLFOX in 2nd line setting, which needs to be further investigated. Updated results, including PK analyses, safety profiles, ORR, PFS and overall survival, will be presented.
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5883;
P3
Updated results, including PK analyses, safety profiles, ORR, PFS and overall survival, will be presented. PAN significantly improved OS vs. BEV in combination with mFOLFOX6 in pts with RAS WT and left-sided mCRC, establishing a standard first-line combination regimen for this population.
- BOLD-100 / Intezyne, Bold Therap
BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy. (Available On Demand; 23) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5068;
P1b
Dose-escalation data supports a BOLD-100 RP2D of 625 mg/m2 for the expansion phase. Progression-free survival, overall survival, and PK data are forthcoming.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Disparity of treatment-related adverse events and outcome in patients with early-onset metastatic colorectal cancer (mCRC). (Available On Demand; 343) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4735;
P3
Distinct genomic profiles could explain some of the disparities. Our findings might improve a personalized management approach in patient selection for chemotherapy, counseling and AE monitoring.